Biosan Biotechnology

Biosan Biotechnology is a professional institution providing one-stop comprehensive solutions for birth defect prevention and control. Based on genetic disease screening and diagnostic technology, it integrates project operation, research and development, sales, discipline services, and child rescue in the field of medical genetics, serving as a nationwide comprehensive service provider for "birth defect prevention and control" and a pioneer in this field in China.
Leveraging its extensive experience in domestic screening, profound understanding and rich practice in the operation and management of birth defect projects, combined with international advanced technological means, Biosan has innovatively deepened the construction of laboratory technology applications and screening system quality control, actively obtaining comprehensive support from multidisciplinary and cross-professional fields such as genetics, management, public health, and supply chain. It has formed a full-industry-chain operation model for "birth defect prevention and control" with technology services as the platform, screening and diagnosis systems as the foundation, and eugenics and health management as the brand core. Since 1999, over 18 years, it has provided products, technical support, talent development, and discipline services to more than 200 screening and genetic centers nationwide, benefiting over 100 million people cumulatively and reducing the social burden of more than 50,000 children with birth defects.
Biosan focuses on providing technology and services for prenatal screening, prenatal diagnosis, newborn genetic metabolic disease screening, and genetic diagnosis projects. It has established strategic cooperation with internationally renowned multinational companies such as PerkinElmer, Waters, Leica, Affymetrix, Illumina, and Agilent. It independently develops and introduces excellent technologies in the industry, builds a nationwide multi-level complementary support network with advanced technology models, steadily promotes data sharing and exchange systems, helps clients enhance the diagnostic capability for complex cases after group screening, and drives innovation in birth defect prevention and control service models through technological innovation. Under the background of precision medicine, it helps clients achieve medical safety, discipline improvement, and self-transcendence with less worry and effort.
Adhering to the corporate mission of "Let every mother enjoy happiness," Biosan, with a global perspective and Chinese services, continuously improves the level of genetic diagnostic technology and services, promotes the equalization of maternal and child health services, screens more disease types, diagnoses and treats more children, serves more populations, and better benefits parent-child families aspiring for a happy life.
Currently, Biosan's annual testing volume reaches 35 million person-times, avoiding the social burden of more than 10,000 children with birth defects each year, with a social value of 20 billion yuan. Meanwhile, the company is actively preparing for an IPO plan. In 2016, the company's sales are expected to exceed 700 million yuan. In the future, the company's revenue will maintain a high growth rate of over 25% annually. Before 2030, Biosan will achieve the "hundred-million-billion" value goals: annual revenue exceeding 10 billion yuan, serving 10 million pregnant women and 10 million newborns annually, and creating 1 trillion yuan in social value.
Biosan Biotechnology website: